4. As of noon trading, Celgene Corporation ( CELG) is down $2.28 (-1.9%) to $115.51 on average volume Thus far, 1.8 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.8 million shares. The stock has ranged in price between $114.88-$118.30 after having opened the day at $117.87 as compared to the previous trading day's close of $117.79. Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies to treat cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $49.0 billion and is part of the drugs industry. The company has a P/E ratio of 35.5, above the S&P 500 P/E ratio of 17.7. Shares are up 50.1% year to date as of the close of trading on Tuesday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.